Today: 14 May 2026
Salesforce stock holds near $228 after MuleSoft AI-agent update as Fed decision nears
24 January 2026
2 mins read

Salesforce stock holds near $228 after MuleSoft AI-agent update as Fed decision nears

New York, Jan 23, 2026, 19:11 EST — After-hours

  • Salesforce (CRM) shares edged down 0.02% to $228.05 on Friday, holding steady in after-hours trading
  • Salesforce unveiled new MuleSoft tools designed to automatically detect and catalog AI “agents” operating across leading cloud platforms
  • Traders are eyeing Monday’s open and next week’s Fed decision to set the tone for rate-sensitive software stocks

Salesforce (CRM) shares edged down 4 cents to $228.05 during Friday’s regular session and barely moved in after-hours trading. Investors digested the company’s new efforts to control the rise of AI “agents” within major corporations. The stock fluctuated between $227.00 and $230.77, starting the day at $226.78.

The timing is key as the software sector lags behind the broader AI tech surge. Investors remain divided over how AI agents will impact subscription revenues. The main concern: if automation handles more tasks, companies might actually require fewer paid users down the line, despite a potential uptick in spending on AI-driven features.

Salesforce is spinning this as a reason to buy deeper into its stack, not pull back. Their angle: control and trust — clear insight into what agents are doing, what they can access, and who’s on the hook when things go wrong.

Salesforce revealed on Thursday that it has upgraded MuleSoft Agent Fabric, its integration software, by adding “Agent Scanners.” These new tools automatically detect and catalog agents across multiple platforms, including Salesforce’s Agentforce, Amazon Bedrock, Google Cloud’s Vertex AI, and Microsoft Copilot Studio. Andrew Comstock, a MuleSoft executive, said companies that tap into the full range of the multicloud AI ecosystem will gain an advantage. AT&T architect Brad Ringer described the framework as “a massive accelerator” for advancing its AI strategy. Salesforce

Salesforce is revamping the partner channel it relies on to roll out its systems. Phil Samenuk, senior VP of alliances and channels for the Americas, told CRN the firm plans to launch a new partner program early in fiscal 2027, which begins Feb. 1. The program will include annual reviews based on certifications and customer outcomes, along with tweaks to incentives and enablement. He noted Salesforce’s ecosystem has “around 16,000-plus partners,” with partners driving over half of Agentforce client projects. Plus, 72% of customers continue using agents after a partner-led rollout. CRN

Stories like that plumbing-and-services angle can break through a sluggish software market: they move the focus from just a “nice demo” to how quickly companies can roll out, manage, and track these tools. Plus, it passes some of the sales load to partners who profit from the implementation work.

A regulatory filing on Friday revealed that Salesforce President and Chief Engineering Officer Srinivas Tallapragada sold 657 shares at $228.09 each to cover taxes from restricted stock unit vesting. This is a standard move related to his compensation.

In its December earnings report, Salesforce raised its full-year revenue forecast to a range between $41.45 billion and $41.55 billion. The company highlighted strong demand for AI capabilities embedded in its cloud offerings, Reuters noted.

Still, the downside risk remains. Should customers cut back on IT budgets or if AI-driven features simply reshape usage without boosting overall subscription revenue, growth could fall short despite a surge in product launches.

With the regular session wrapped for the week, focus shifts to the macro front: the Federal Reserve’s meeting on Jan. 27-28, with a rate decision expected Jan. 28, will probably influence growth stocks. Earnings from major tech firms around that time could also shift risk sentiment, and software companies like Salesforce usually follow those trends.

Stock Market Today

  • Nurix Therapeutics Stock: Is Its Premium 23.3x Price-to-Sales Multiple Justified?
    May 14, 2026, 9:02 AM EDT. Nurix Therapeutics (NRIX) shares rose 1.38% to $16.18 amid mixed recent performance, down 10% year to date but up nearly 69% over one year. The stock trades at a high price-to-sales (P/S) multiple of 23.3x, well above the US biotech average of 9.7x. This premium reflects strong analyst revenue growth forecasts of 42.2% annually, outpacing the broader market. However, Nurix remains loss-making with $295 million in ongoing losses and a $1.65 billion market cap, making it vulnerable to clinical setbacks. Investors should weigh the high growth potential against risks in this early-stage biotech before assuming the premium valuation is sustainable.

Latest articles

Apple Backs Google in EU AI Fight as iPhone Rules Loom

Apple Backs Google in EU AI Fight as iPhone Rules Loom

14 May 2026
Apple warned the European Commission that proposed EU rules forcing Google’s Android to open core features to rival AI assistants could endanger privacy, security, and device performance. The Commission’s feedback period closed Wednesday, with a final decision expected by July 27. Apple argued the measures could set a precedent for its own platforms. Google also opposes the plan, calling it an “unwarranted intervention.”
Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

14 May 2026
Precigen shares jumped 14.1% in early trading after first-quarter revenue reached $23.3 million, beating estimates, and net loss narrowed to $7.9 million from $54.2 million a year earlier. Papzimeos, its new RRP therapy, generated $21.6 million in net product revenue. The company ended March with $56.7 million in cash and expects current funds and Papzimeos sales to last through 2026.
POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

14 May 2026
POET Technologies signed a supply and joint-development agreement with Lumilens, including a $50 million initial order for optical engines used in AI data-center networks. The companies said cumulative purchases could exceed $500 million over five years. POET shares rose 16% after the news. First engineering samples are expected in late 2026, with production targeted for 2027.
CoreWeave (CRWV) stock price swings late as insider sale filing and lawsuit keep shares in focus
Previous Story

CoreWeave (CRWV) stock price swings late as insider sale filing and lawsuit keep shares in focus

Exxon Mobil stock price rises after-hours as XTO shops $1 billion Eagle Ford assets ahead of Q4 results
Next Story

Exxon Mobil stock price rises after-hours as XTO shops $1 billion Eagle Ford assets ahead of Q4 results

Go toTop